NCT04262557View on ClinicalTrials.gov

Sunrise® a New Medical Device to Diagnose Sleep Apnea Syndrome

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 18, 2020

Primary Completion Date

September 28, 2020

Study Completion Date

September 28, 2020

Conditions
Sleep Apnea Syndrome, Obstructive
Interventions
DIAGNOSTIC_TEST

Sunrise® solution

Type II medical device with the CE label. It is a chin sensor associated to an integrated and connected platform.

DIAGNOSTIC_TEST

Polysomnography

Gold standard method to diagnose SAS used as comparator

Trial Locations (1)

Unknown

University Hospital Grenoble Alpes, Grenoble

All Listed Sponsors
collaborator

Sunrise

INDUSTRY

collaborator

Icadom

INDUSTRY

collaborator

DOCAPOST

UNKNOWN

lead

University Hospital, Grenoble

OTHER

NCT04262557 - Sunrise® a New Medical Device to Diagnose Sleep Apnea Syndrome | Biotech Hunter | Biotech Hunter